Roivant Sciences Ltd.
About Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2026
- $8.3M
- Net income
- -$299.8M
- Total assets
- $5.7B
- Market cap
- $20.6B
- Operating margin
- -6235.7%
- Net margin
- -4817.3%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $8.3M
- Operating expenses
- $1.3B
- Operating income
- -$515.1M
- Income tax
- $133.3M
- Net income
- -$397.9M
- EPS (basic)
- $-0.43
- EPS (diluted)
- $-0.54
Balance sheet
- Total assets
- $5.7B
- Current assets
- $5.2B
- Total liabilities
- $416.3M
- Current liabilities
- $281.2M
- Shareholders’ equity
- $5.3B
Cash flow
- Operating cash flow
- -$750.3M
- Investing cash flow
- -$682.3M
- Financing cash flow
- $134.2M
- Net cash flow
- -$1.3B
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $20.6B
- EPS (diluted)
- $-0.54
- Shares outstanding
- 721.5M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 1, 2021
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $299.8M in FY2026.
- Revenue declined 85% from FY2022 to FY2026.
- Trading 12% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Roivant Sciences Ltd..
Write a review
News about Roivant Sciences Ltd.
News & sentiment via Polygon.io
